Drug Profile
Evofosfamide - Molecular Templates
Alternative Names: HAP 302; TH-302; TH302-cpdLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Threshold Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
- Developer Grupo Espanol de Tumores Neuroendocrinos; Merck KGaA; Molecular Templates; Threshold Pharmaceuticals; University of Texas Health Science Center at San Antonio; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Nitroimidazoles; Phosphoramide mustards; Small molecules
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Pancreatic cancer
- Phase II Biliary cancer; Glioblastoma
- Suspended Leukaemia; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours
- Discontinued Soft tissue sarcoma
Most Recent Events
- 28 Dec 2022 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 31 May 2022 Immunogenesis enters into a collaboration agreement with Agenus to support a clinical trial evaluating the combination of balstilimab, zalifrelimab with evofosfamide for treatment of Solid tumours
- 31 May 2022 Agenus in collaboration with Immunogenesis plans a clinical trial for Solid tumours (Combination therapy, Late-stage disease)